Sign In
Buy RXRX
$3.52
+0.180 (+5.39%)
At Close: Jun 26, 2026
Cathie Wood Owns These 2 AI Stocks. Should You?
06:15am, Monday, 03'rd Jun 2024
Meta Platforms has made several key moves in the field of artificial intelligence, but the company's opportunities go far beyond this industry. Recursion Pharmaceuticals has a promising approach to so
Is Recursion Pharmaceuticals Stock a Millionaire-Maker?
03:40am, Sunday, 02'nd Jun 2024
Recursion Pharmaceuticals hopes to use AI to accelerate drug discovery in the healthcare industry. its ambitious plans are still unproven, and the business has no approved products of its own.
Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool
03:27pm, Wednesday, 29'th May 2024
Published open-access today in Nature Genetics, “High-resolution genome-wide mapping of chromosome-arm-scale truncations induced by CRISPR–Cas9 editing” identifies novel evidence of a proximity
2 Cathie Wood Biotech Stocks That Could Be Worth the Risk
06:00am, Wednesday, 29'th May 2024
Cathie Wood likes to invest in risky biotech stocks. Ginkgo Bioworks has ambitions to disrupt biopharma manufacturing.
Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board
04:30pm, Friday, 24'th May 2024
Dr. Hershberg is a current board member with over 25 years of experience as a physician, scientist, and entrepreneur Dr. Hershberg is a current board member with over 25 years of experience as a physi
2 Stocks That Could 10x by 2035
06:30am, Friday, 24'th May 2024
Viking Therapeutics is looking to make noise in a fast-growing therapeutic area. Recursion Pharmaceuticals' approach could change the way we develop drugs.
Here is What to Know Beyond Why Recursion Pharmaceuticals, Inc. (RXRX) is a Trending Stock
10:02am, Thursday, 23'rd May 2024
Recursion Pharmaceuticals (RXRX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
National Bank of Canada FI Buys 1,500 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
05:07am, Monday, 20'th May 2024
National Bank of Canada FI raised its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 90.9% during the fourth quarter, according to its most recent disclosure with the Se
What's the Difference Between Biotech Stocks and TechBio Stocks?
08:45am, Wednesday, 15'th May 2024
Some high-tech biotechs claim to be "TechBio" companies. The term signals the use of an automation-heavy approach to biotech.
Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry
05:00am, Monday, 13'th May 2024
BioHive-2, an NVIDIA DGX SuperPOD with NVIDIA DGX H100 systems, ranked #35 in the TOP500 list of the most powerful supercomputers in the world across all industries as of May 2024. BioHive-2, an NVIDI
Cathie Wood Is Buying This Under-the-Radar AI Stock
08:15am, Sunday, 12'th May 2024
Recursion Pharmaceuticals, an AI-focused biotech, makes up more than 5% of one of Ark Invest's ETFs. The company's approach looks promising, but it has yet to produce the kinds of results investors wa
Recursion Pharmaceuticals CEO Chris Gibson goes one-on-one with Jim Cramer
07:48pm, Friday, 10'th May 2024
Recursion Pharmaceuticals Co-Founder and CEO Chris Gibson joins 'Mad Money' host Jim Cramer to talk integrating machine learnings into drug development and partnering with Nvidia.
We've built an unbiased platform that lets data drive decisions, not us, says Recursion CEO
07:47pm, Friday, 10'th May 2024
Recursion Pharmaceuticals Co-Founder and CEO Chris Gibson joins 'Mad Money' host Jim Cramer to talk integrating machine learnings into drug development and partnering with Nvidia.
Recursion Pharmaceuticals, Inc. (RXRX) Q1 2024 Earnings Call Transcript
10:53pm, Thursday, 09'th May 2024
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX ) Q1 2024 Earnings Conference Call May 9, 2024 5:00 PM ET Company Participants Chris Gibson - Co-Founder & Chief Executive Officer Conference Call Particip
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Tops Revenue Estimates
06:26pm, Thursday, 09'th May 2024
Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.34 per share a year ago.
